Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy


Sen F., Tambas M. , Ozkaya K. , Guveli M. E. , Ciftci R. , Ozkan B. , ...Daha Fazla

MEDICINE, cilt.95, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.